WuXi XDC Cayman Inc (Ticker: 2268 HK), a company in the Medical - Biomedical/Gene industry, announced an Initial Public Offering on November 7, 2023. The firm, a Wuxi Biologics subsidiary specializing in contract research and manufacturing services in the pharmaceutical and biotechnology sectors, is based in China and will list on the Hong Kong Stock Exchange. WuXi XDC Cayman Inc plans to raise HKD 3.68 billion (USD 470.09 million) through the offering. The expected price range for the shares is HKD 19.90 to 20.60. A total of 178.45 million shares will be offered. The listing is tentatively scheduled for November 17, 2023. The offering is managed by China International Capital Corp HK Securities, Citigroup Global Markets Asia Ltd, Goldman Sachs (Asia), Huatai Financial Holdings Hong Kong Ltd, and Morgan Stanley Asia Ltd. The IPO is part of a strategic move to expand WuXi XDC's contract services in a growing market, with parent WuXi Biologics set to reduce its stake to 50.9% post-listing.